泡沫之夏

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

一 |     Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。    四季度是冲刺年度目标任务、打好“收官战”的关键期。         　　进入四季度，全市多个重点项目开足马力建设，劳动者们在施工和产业一线，对标对表抢工期、赶进度、保质量，为高质量发展增添新动能。         　　在抚顺高新区，辽宁星聖精细化工有限公司 5000 吨/年单乙烯基二乙二醇醚生产装置项目建设正酣。目前，该项目土建工程进入收尾阶段，未来两个月设备将陆续到场，力争今年年底具备试生产条件。         　　辽宁星聖精细化工有限公司是一家集储、运、工、贸为一体的新兴精细化工企业。此项目选址于高新技术产业园区碾盘工业园区，不仅填补了东北市场生产空白，还解决了高新区企业原料需求，完善了当地产业链条。项目投产后，将形成每年 5000 吨单乙烯基二乙二醇醚及约 2000 吨三甘醇、乙二醇等附属产品的生产规模，预计年产值可达 1.26 亿元，利润超 3000 万元，纳税近千万元。         　　项目开工建设以来，抚顺高新区给予大力支持，为项目的顺利推进提供坚实保障。企业计划在一期项目建成投产后，依托目前一期公用工程基础建设二期项目。届时，项目规模将扩充至20000吨/年单乙烯基二乙二醇醚生产能力，年产值预计可达约6亿元。

二 | 产品销售将立足抚顺地区，辐射东北市场，为区域经济发展贡献力量。         　　与此同时，沈阳润驰润滑油添加剂项目推进态势良好，各项工作有序开展。

三 | 据悉，该项目总投资 1.5 亿元，占地 28058 平方米，采用先进生产技术和智能化设备，致力于打造高质量、高性能的润滑油添加剂产品。

四 | 其生产的聚甲基丙烯酸酯型润滑油添加剂能有效提高油品粘度指数，降低凝固点，产品涵盖黏度指数改进剂和降凝剂，技术先进且安全环保。项目投产后将与多家央企合作并出口国外市场。         　　这些大项目的竞相落地，不仅仅是一个个经济数据的增长，更是抚顺市工业转型升级的生动写照。它们带来了先进的技术、创新的理念和广阔的市场，吸引了大量的人才和资金流入。同时，也为周边产业的发展提供了机遇，带动了相关配套企业的成长。         　　近年来，我市工业经济蓬勃发展。新开工项目如雨后春笋般不断涌现，涵盖化工、润滑油添加剂等多个领域，重大项目推进上取得的显著成效，是抚顺经济高质量发展的生动注脚，为我市的经济腾飞增添了强劲动力，推动城市迈向新的发展高度。未来，我市将继续坚持以项目为王的理念，加大对工业项目的扶持力度，不断优化营商环境，吸引更多的优质项目落地生根，为区域经济高质量发展注入更多“强引擎”，在新征程上奋力实现抚顺全面振兴取得新突破。                   责任编辑：刘春阳。

五 |

Current article:http://p1xhbtn.xiongpeiduanlouduoennongleng.cyou/list_5uceau/76sp.html

Published on:09:42:24